NeoChord Appoints David Chung as President and CEO

EDEN PRAIRIE, Minn., June 24, 2014—NeoChord, a medical device company focused on minimally invasive mitral valve repair, announced today that it has appointed David H. Chung as President and CEO, effective immediately, replacing John Seaberg, who resigned.

“I am extremely pleased to join NeoChord at this exciting time in its evolution. The company has established a commercial beachhead in Europe for its technology, which allows for the implantation of artificial chordae tendinae, a proven technique for the repair of mitral valve prolapse, via a transapical, off-pump procedure,” said David Chung.

Read more: NeoChord appoints David Chung as President and CEO